Drugs / BBP-711
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04876924 | Apr 2021 → Feb 2022 | — | Cantero Therapeutics, a BridgeBio company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-06-27 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma announces positive phase 1 data and phase 2/3 trial design for bbp-711, a potentially best-in-class go inhibitor for primary hyperoxaluria type 1 (ph1) and recurrent kidney stone formers bridgebio.com ↗
The data were shared in a feature oral presentation at European Society for Pediatric Nephrology (ESPN) 2022, taking place in Ljubljana, Slovenia. |
| 2021-11-04 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma reports third quarter 2021 financial results and business update bridgebio.com ↗
BridgeBio announced preliminary Phase 1 data in which BBP-711 was well-tolerated and resulted in maximal increases in plasma glycolate exceeding those achieved by any GO-targeting agents reported in healthy adult volunteers. |
| 2021-10-12 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma announces progress in its kras portfolio, new gene therapy programs, and updates on advancements across its r&d pipeline targeting genetic diseases and cancers bridgebio.com ↗
BridgeBio will share preliminary Phase 1 data in which BBP-711 was well-tolerated and resulted in maximal increases in plasma glycolate exceeding those achieved by any GO-targeting agents reported in healthy adult volunteers. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-27 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma announces positive phase 1 data and phase 2/3 trial design for bbp-711, a potentially best-in-class go inhibitor for primary hyperoxaluria type 1 (ph1) and recurrent kidney stone formers bridgebio.com ↗ |
| 2021-11-04 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma reports third quarter 2021 financial results and business update bridgebio.com ↗ |
| 2021-10-12 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma announces progress in its kras portfolio, new gene therapy programs, and updates on advancements across its r&d pipeline targeting genetic diseases and cancers bridgebio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBP-711 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04876924 ↗ |
| Route | Oral | “A single dose of BBP-711 will be administered orally.” NCT04876924 ↗ |